Sun Pharma Launches Semaglutide Injections in India Under Noveltreat and Sematrinity Brands
Mumbai, India, March 21, 2026 – Sun Pharmaceutical Industries Limited today announced the launch of its semaglutide injection under the brand names Noveltreat and Sematrinity in India, available in all strengths. Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced-calorie diet & increased physical activity and is available in five dose strengths - 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. Sematrinity is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet & exercise and is available in two dose strengths - 2 mg/1.5 mL and 4 mg/3 mL.Weekly therapy costs range from approximately ₹900 to ₹2,000 for Noveltreat and ₹ 750 to ₹1, 300 for Sematrinity.
“With the launch of Noveltreat and Sematrinity, our endeavor is to provide a high-quality, affordable therapy to a wider patient community in India," said Kirti Ganorkar, Managing Director, Sun Pharmaceutical Industries Ltd.
Noveltreat’s prefilled pen uses a concealed needle to ease injection fear and improve handling safety and dosing accuracy. Sematrinity comes in a multi-dose pen format that offers flexible dosing, with a smooth dialer that enables accurate dose delivery. The pens are manufactured in Europe.
GLP-1 agonists are a class of medications utilized to treat type 2 diabetes mellitus (T2DM) and obesity. According to the National Family Health Survey-5 (NFHS-5), almost one in four Indians between the age group 15-49 is now overweight or obese. As per the ICMR INDIAB 17 study published in 2023 an estimated 101.3 million people had diabetes in India.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.